학술논문

Genetic screening in sporadic ALS and FTD
Document Type
article
Source
Journal of Neurology Neurosurgery & Psychiatry. 88(12)
Subject
Genetics
Frontotemporal Dementia (FTD)
Brain Disorders
Rare Diseases
Neurodegenerative
Dementia
Acquired Cognitive Impairment
Neurosciences
Clinical Research
ALS
Neurological
Amyotrophic Lateral Sclerosis
C9orf72 Protein
Frontotemporal Dementia
Genetic Testing
Humans
Reproducibility of Results
C9ORF
FRONTOTEMPORAL DEMENTIA
GENETICS
Medical and Health Sciences
Psychology and Cognitive Sciences
Neurology & Neurosurgery
Language
Abstract
The increasing complexity of the genetic landscape in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) presents a significant resource and physician training challenge. At least 10% of those diagnosed with ALS or FTD are known to carry an autosomal dominant genetic mutation. There is no consensus on what constitutes a positive family history, and ascertainment is unreliable for many reasons. However, symptomatic individuals often wish to understand as much as possible about the cause of their disease, and to share this knowledge with their family. While the right of an individual not to know is a key aspect of patient autonomy, and despite the absence of definitive therapy, many newly diagnosed individuals are likely to elect for genetic testing if offered. It is incumbent on the practitioner to ensure that they are adequately informed, counselled and supported in this decision.